[{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 20, 2024

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : With these results, the company initiates the planning of AIR 2, a double-blind controlled phase 2 dose-finding study to confirm these results and accelerate the development of C21 in parallel to completing the AIR trial.

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 02, 2022

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The AIR trial1 is an open label single arm phase 2 trial in treatment naïve IPF patients in which 100 mg of C21 (VP01) was administered twice daily for 24 weeks with an optional 12-week extension.

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 17, 2022

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Orphan Reach

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as ...

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 10, 2022

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : The study is a phase II, multi-center, open-label, single-arm trial investigating the safety, effect on lung function and pharmacokinetics of C21 in 60 subjects with IPF.

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Indo Livestock Expo
                          Not Confirmed
                          Indo Livestock Expo
                          Not Confirmed

                          Details : Fresh human IPF lung tissue harvested from a patient during lung transplantation showed stable expression of the VP01 target, AT2R, and treatment with clinically relevant concentrations of VP01 caused a dose-dependent decrease of TGFb1.

                          Product Name : C21

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 25, 2020

                          Lead Product(s) : Buloxibutid

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank